Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia Friedreich’s...
Biogen to Realign Resources for Alzheimer's Disease Franchise Company to reprioritize resources allocated to ADUHELM® (aducanumab-avwa...
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission CAMBRIDGE, Mass., Dec. 19...
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative...
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. ZURZUVAE, the...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.